MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference
March 08 2022 - 6:05AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that its Chief Executive Officer, Michael
Castagna, PharmD, will participate in a virtual presentation at the
Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15,
2022 at 4:00 pm (ET).
Interested parties can access a link to the webcast from the
News & Events section of the Company’s website at Events &
Presentations. The webcast replay will remain available for 14 days
following the live presentation.
About MannKind CorporationMannKind
Corporation (Nasdaq: MNKD) focuses on the development and
commercialization of inhaled therapeutic products for patients with
endocrine and orphan lung diseases. MannKind is currently
commercializing Afrezza® (insulin human) Inhalation Powder, the
Company’s first FDA-approved product and the only inhaled ultra
rapid-acting mealtime insulin in the United States, where it
is available by prescription from pharmacies nationwide. Afrezza is
also available by prescription in Brazil, where it is
commercialized by the Company’s partner, Biomm
SA. MannKind was established in 1991, and is located
in Danbury, Conn., and Westlake Village, Calif. The
Company also employs field sales and medical representatives across
the U.S. Please visit mannkindcorp.com to learn
more.
Company Contact:Rose Alinaya,
Investor Relations(818) 661-5000Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024